We help biotech investors prioritize and steer their investment portfolio.
F E A T U R E S
Estimating the revenue potential of an investigational drug is a complex task, which is inherently uncertain. We conduct for you a thorough analysis and consider various factors to make informed decisions:
Market size
Are you looking at the right patient segment ? Will the clinical trial results be generalizable to a broader target population? What is the market size?
Competitive analysis
What is the current and future competitive landscape? Are there evident unmet medical needs the product can address? What is the market share estimate?
Pricing strategy
What are implications of the price regulation in Europe? What is the sustainable price for a drug? How to balance a drug affordability with profitability?
Clinical data evidence
Does the clinical trial design fulfill regulated reimbursement requirements? National reimbursement authorities have specific data evidence requirements, that can differ from those for marketing authorization. On top, they follow market dynamics and often lead to data evidence gaps. How to mitigate those evidence gaps?
Reimbursement risk
What is the likelihood of a positive national pricing & reimbursement decision? Can we anticipate any caveats? What is the time lag between marketing authorization and patient access that will affect your revenue start date?
Limitations
Are there any limitations expected in patient access? Will there be any managed access agreements? Is a population restriction expected? How will this affect the market share estimates?
At Sur, due diligence for investors involves a meticulous process of quantifying risks and confirming value to ensure that all relevant market access information is thoroughly assessed before making critical business decisions.
Valuation confirmation
Value proposition stress test
Reimbursement likelihood
Price potential
Potential returns
Competitive analysis
Market share estimates
Time to patient access
Pricing scenarios
Estimated revenue potential
